The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese
Most of type 2 diabetes are characterized by being overweight or obese mainly caused by insulin resistance. GLP-1 receptor agonist has been proved to help to lose weight and improve insulin resistance. In this study, we suppose that GLP-1 receptor agonist has the effect of inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese and has its advantages
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
First Hospital of Jilin University
Changchun, Jilin, China
Rate of Inducing Diabetes Remission
Time frame: At the end of 12-week treatment
Change of Rate of Maintaining Diabetes Remission
Time frame: 3,6,12,24,36 months after 12-week treatment
Time of Maintaining Diabetes Remission
Time frame: up to 36 months after 12-week treatment
Change of Blood Pressure
Time frame: Baseline and 0,3,6,12,24,36 months after 12-week treatment
Change of Heart Rate
Time frame: baseline and 0,3,6,12,24,36 months after 12-week treatment
Change of Weight
Time frame: baseline and 0,3,6,12,24,36 months after 12-week treatment
Change of Waistline
Time frame: baseline and 0,3,6,12,24,36 months after 12-week treatment
Change of Glycosylated Hemoglobin
Time frame: baseline and 0,3,6,12,24,36 months after 12-week treatment
Change of Pancreatic Beta-cell Function
Pancreatic Beta-cell Function will be evaluated by insulin releasing test. The fasting and 2-hour postprandial plasma glucose concentrations and serum insulin concentrations will be tested.
Time frame: baseline and 0,3,6,12,24,36 months after 12-week treatment
Change of Insulin Resistance Index
Time frame: baseline and 0,3,6,12,24,36 months after 12-week treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Incidence of Hypoglycemia
Time frame: During the 12-week treatment
The Incidence of Diabetic Retinopathy
Time frame: up to 36 months after 12-week treatment
The Incidence of Diabetic Nephropathy
Time frame: up to 36 months after 12-week treatment